Losartan: A review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy

Drugs

Volumn 65, Issue 18, 2005, Pages 2657-2674

  Moen, Marit D ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; HYDROCHLOROTHIAZIDE; LOSARTAN; LOSARTAN POTASSIUM; PHENOBARBITAL; RIFAMPICIN; WARFARIN;

ALBUMINURIA; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ASTHENIA; BACKACHE; BLOOD PRESSURE; BRADYCARDIA; CANCER; CAROTID ARTERY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPNEA; ELECTROCARDIOGRAM; FATIGUE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; LEG EDEMA; MORBIDITY; MORTALITY; NEGRO; NONHUMAN; PNEUMONIA; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CEREBROVASCULAR ACCIDENT; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; RANDOMIZED CONTROLLED TRIALS; RISK;

ANIMALIA;

EID: 30144444977     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565180-00012     Document Type: Review

References (83)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. National High Blood Pressure Education Program Co-ordinating Committee. JAMA 2003 May 21; 289 (19): 2560-72
2. American Heart Association. Heart disease and stroke statistics: 2005 update [online]. Available from URL: http://www.americanheart.org/downloadable/ heart/1105390918119HDSStats2005Update.pdf [Accessed 2005 Aug 31]
3. Laurent S. Guidelines from the British Hypertension Society: the lower the pressure the better. BMJ 2004 Mar 13; 328 (7440): 593-4
4. Izzo Jr JL, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am 2004 Sep; 88 (5): 1257-71
5. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension [published erratum appears in J Hypertens 2003 Nov; 21 (11): 2203-4]. J Hypertens 2003; 21 (6): 1011-53
6. Chalmers J, Todd A, Chapman N, et al. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. International Society of Hypertension Writing Group. J Hypertens 2003 Apr; 21 (4): 651-63
7. Mancia G. Prevention and treatment of stroke in patients with hypertension. Clin Ther 2004; 26 (5): 631-48
8. Olsen MH, Wachtell K, Neland K, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension: a LIFE substudy. Blood Press 2005; 14 (3): 177-83
9. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003 Dec 2; 139 (11): 901-6
10. Høieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. The LIFE study group. Kidney Int 2004; 65 (3): 1041-9
11. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary [published erratum appears in BMJ 2004 Apr 17; 328 (7445): 926]. BMJ 2004 Mar 13; 328 (7440): 634-40
12. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996 May; 51 (5): 820-45
13. Waugh J, Keating G. Losartan: in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy. Am J Cardiovasc Drug 2003; 3 (5): 371-7
14. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993 Jan; 6 (1): 28-32
15. Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000 Apr 11; 101 (14): 1653-9
16. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000 Apr 4; 101 (13): 1586-93
17. 2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997 Jun; 281 (3): 1065-70
18. 2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998 Aug; 32 (2): 198-205
19. Guerra-Cuesta JI, Montón M, Rodríguez-Feo JA, et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17 (3): 447-52
20. Schwemmer M, Sommer O, Bassenge E. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther 2001 Jul; 15 (4): 301-7
21. Levy PJ, Yunis C, Owen J, et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000 Dec 1; 86 (11): 1188-92
22. Erdem Y, Usalan C, Haznedaroglu ÍC, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999 Nov; 12 (11 Pt 1): 1071-6
23. Boman Sr KO, Olsen MH, Wachtell K, et al. The effect of losartan versus atenolol on hemostasis and fibrinolysis in hypertensive patients with left ventricular hypertrophy: a LIFE substudy [abstract no. 1085-193]. J Am Coll Cardiol 2004 Mar 3; 43 (5 Suppl. A): 482
24. Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004 Sep; 22 (9): 1805-11
25. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE study group. Lancet 2002 Mar 23; 359 (9311): 995-1003
26. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation 2003 Jul 28; 108 (6): 684-90
27. Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint reduction in hypertension (LIFE) trial. Circulation 2004 Sep 14; 110 (11): 1456-62
28. de Champlain J. Do angiotensin II antagonists provide benefits beyond blood pressure reduction? Adv Ther 2005 Mar-Apr; 22 (2): 117-36
29. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens 2005 Jul 28. Epub ahead of print
30. Fournier A, Messerli FH, Achard JM, et al. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004 Apr 21; 43 (8): 1343-7
31. Conlin PR. Redefining efficacy of antihypertensive therapies beyond blood pressure reduction: the role of angiotensin II antagonists. Int J Clin Pract 2005 Feb; 59 (2): 214-24
32. Merck & Co., Inc. COZAAR (losartan potassium tablets): prescribing information (US) [online]. Available from URL: http://www.cozaar.com/cozaar/ shared/documents/pi_cozaar.pdf [Accessed 2005 Aug 15]
33. Merck Sharp & Dohme Limited. COZAAR 25 mg, 50 mg and 100 mg tablets: prescribing information (UK) [online]. Available from URL: http://emc.medicines. org.uk/ [Accessed 2005 Aug 15]
34. Lindholm LH, Ibsen H, Dalhöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE study group. Lancet 2002; 359 (9311): 1004-10
35. Kjeldsen SE, Dahlöf B., Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint reduction (LIFE) substudy. The LIFE study group. JAMA 2002 Sep 25; 288 (12): 1491-8
36. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005 Mar 1; 45 (5): 705-11
37. Devereux RB, Dahlöf B, Kjeldsen SE, et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial: the LIFE study group. Ann Intern Med 2003 Aug 5; 139 (3): 169-77
38. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004 Mar 17; 43 (6): 1047-55
39. Olsen MH, Wachtell K, Tuxen C, et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005 May; 23 (5): 1083-90
40. Olsen MH, Fossum E, Høieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005 Apr; 23 (4): 891-8
41. Olsen MH, Wachtell K, Beevers G, et al. Losartan has positive effects on lipid metabolism compared to atenolol in patients with hypertension and electrocardiographic left ventricular hypertrophy: the LIFE study [abstract no. 1129-107]. J Am Coll Cardiol 2005 Feb 1; 45 (3 Suppl. A): 423A
42. Zhu JR, Bai J, Cai NS, et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract 2004 Dec; 58 Suppl. 145: 46-9
43. Smith DHG, Dubiel R, Jones M, et al. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41-50
44. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003 Apr 2; 41 (7): 1148-55
45. Picca M, Agozzino F, Pelosi G, et al. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004 Mar-Apr; 21 (2): 76-86
46. Sica DA, Gehr TWB, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005; 44 (8): 797-814
47. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995 Dec; 58 (6): 641-9
48. Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE study group. Am J Hypertens 1997 Jul; 10 (7 Pt 1): 705-13
49. Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. The LIFE study group. Hypertension 1998 Dec; 32 (6): 989-97
50. Kizer JR, Dahlöf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005 Jan; 45 (1): 46-52
51. Wolf PA, D'Agostino RB, O'Neal MA, et al. Secular trends in stroke incidence and mortality: the Framingham Study. Stroke 1992 Nov; 23 (11): 1551-5
52. Kjeldsen SE, Lyle PA, Kizer JR, et al. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy: the LIFE study. J Clin Hypertens (Greenwich) 2005 Mar; 7 (3): 152-8
53. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005 Mar 1; 45 (5): 712-9
54. Lindholm LH, Dahlöf B, Edelman JM, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003 Aug 23; 362 (9384): 619-20
55. Reims HM, Oparil S, Kjeldsen SE, et al. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press 2004; 13 (6): 376-84
56. Reims HM, Kjeldsen SE, Brady WE, et al. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. J Hum Hypertens 2004 Jun; 18 (6): 381-9
57. Os I, Oparil S, Kjeldsen SE, et al. Female sex and effect of losartan versus atenolol in patients with hypertension and left ventricular hypertrophy: the LIFE study [abstract no. 1014-135]. J Am Coll Cardiol 2005 Feb 1; 45 (3 Suppl. A): 374A
58. Franklin SS, Wachtell K, Papademetriou V, et al. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension 2005 Sep; 46 (3): 492-9
59. Jönsson B, Carides GW, Burke TA, et al. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. The LIFE study group. J Hypertens 2005 Jul; 23 (7): 1425-31
60. Szucs TD, Burnier M, Erne P. Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective. Cardiovasc Drugs Ther 2004 Sep; 18 (5): 391-7
61. Boersma C, Carides GW, Burke TA, et al. Cost-effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for The Netherlands based on the LIFE-study [abstract no. PST2]. Value Health 2005 Nov-Dec; 8 (6): 150-1.
62. Plus poster presented at the 8th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6-8; Florence
63. Ruilope LM, Burke TA, Carides GW, et al. Cost-effectiveness of losartan in patients with hypertension and LVH in Spain: an economic evaluation based on the LIFE trial [abstract no. PCV15]. Value Health 2004 Nov-Dec; 7 (6): 689
64. Anis AH, Sun H, Singh S, et al. A cost-utility analysis of losartan versus atenolol in the treatment of mild to moderate hypertension [abstract no. PCV17]. Value Health 2004 May-Jun; 7 (3): 323
65. Chevreul K, Durand-zaleski I, Souchet T. Economic evaluation of losartan compared with atenolol in the treatment of hypertension with left ventricular hypertrophy: cost-minimization analysis based on LIFE study [abstract no. PCV59]. Value Health 2003 Nov-Dec; 6 (6): 666
66. Baguet J-P, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005; 5 (2): 131-40
67. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-97
68. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000 Dec 9; 356: 1955-64
69. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004 Nov 6; 364 (9446): 1684-9
70. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 Oct 29; 366 (9496): 1545-53
71. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003 May; 21 (5): 875-86
72. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004; 22 (8): 1605-12
73. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The VALUE trial group. Lancet 2004 Jun 19; 363: 2022-31
74. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003 Apr 1; 138 (7): 542-9
75. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005 Jun; 36 (6): 1218-26
76. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000 May 6; 355 (9215): 1582-7
77. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002 Sep 7; 360 (9335): 752-60
78. Messerli FH. The LIFE study: the straw that should break the camel's back. Eur Heart J 2003; 24 (6): 497-89
79. Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001 Aug; 23 (8): 1193-208
80. Douglas JG, Bakris GL, Epstein M, et al. Management of High Blood Pressure in African Americans. Consensus statement of the hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003 Mar 10; 163 (5): 525-41
81. Dahlöf B, Burke TA, Krobot K, et al. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004 Jun; 18 (6): 367-73
82. Merck & Co., Inc. FDA approves COZAAR as the first and only hypertension medicine to help prevent stroke in patients with hypertension and left ventricular hypertrophy [online]. Available from URL: http://www.merck.com [Accessed 2003 Mar 27]
83. Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 2003; 21 Suppl. 6: S37-46